Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

Chemical Formula: -

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Associated Therapies: -

Clinical Trials

Ketogenic Diet vs ACTH for the Treatment of Children With West Syndrome

Phase 2

Active, not recruiting

Conditions: Ketogenic Diet
West Syndrome
Infantile Spasm
ACTH

Interventions: Dietary Supplement: Ketogenic diet
Drug: ACTH

First Posted Date: 2022-03-15

Last Posted Date: 2024-06-25

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 80

Registration Number: NCT05279118

Locations: 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
AIIMS, New Delhi, India

Treatment of Refractory Gout With ACTH or Methylprednisolone

Not Applicable

Conditions: Gout

Interventions: Drug: Methylprednisolone Injection
Drug: Adrenocorticotropic Hormone

First Posted Date: 2021-03-22

Last Posted Date: 2021-03-22

Lead Sponsor: Shanghai 10th People's Hospital

Target Recruit Count: 60

Registration Number: NCT04808856

Locations: 🇨🇳
Shanghai Tenth People's hospital, Shanghai, Shanghai, China

Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)

Not Applicable

Completed

Conditions: Primary Aldosteronism

Interventions: Drug: Adrenocorticotropic hormone

First Posted Date: 2020-07-08

Last Posted Date: 2023-12-29

Lead Sponsor: Chongqing Medical University

Target Recruit Count: 228

Registration Number: NCT04461535

Locations: 🇨🇳
The First Affilated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

ACTH vs Betamethasone in Hospitalized Patients With Acute Gout

Not Applicable

Conditions: Gout Attack

Interventions: Drug: ACTH
Drug: Betamethasone

First Posted Date: 2020-03-13

Last Posted Date: 2020-03-13

Lead Sponsor: University of Patras

Target Recruit Count: 60

Registration Number: NCT04306653

Locations: 🇬🇷
University Hospital of Patras, PAtras, Achaia, Greece

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Phase 4

Completed

Conditions: Keratitis

Interventions: Drug: Acthar

First Posted Date: 2019-11-19

Last Posted Date: 2021-08-18

Lead Sponsor: Mallinckrodt

Target Recruit Count: 36

Registration Number: NCT04169061

Locations: 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸
Global Research Management, Inc., Glendale, California, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States

and more 6 locations

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Early Phase 1

Recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: ACTH
Drug: rhCG

First Posted Date: 2019-04-05

Last Posted Date: 2023-11-03

Lead Sponsor: University of Virginia

Target Recruit Count: 144

Registration Number: NCT03905603

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

Early Phase 1

Completed

Conditions: Proliferative Vitreoretinopathy

Interventions: Drug: Adrenocorticotropic Hormone

First Posted Date: 2018-11-01

Last Posted Date: 2023-08-08

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 11

Registration Number: NCT03727776

Locations: 🇺🇸
Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Conditions: Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function

First Posted Date: 2018-08-23

Last Posted Date: 2020-02-05

Lead Sponsor: Greater Boston Medical Associates

Target Recruit Count: 40

Registration Number: NCT03644771

Locations: 🇺🇸
Greater Boston Medical Associates 211 West St., Milford, Massachusetts, United States

(ACTH) for the Treatment of Sarcoid Uveitis

Conditions: Sarcoid Uveitis

Interventions: Drug: H.P. Acthar gel

First Posted Date: 2018-03-22

Last Posted Date: 2018-03-22

Lead Sponsor: John Huang, MD

Target Recruit Count: 10

Registration Number: NCT03473964

Locations: 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: ACTHar

First Posted Date: 2018-02-05

Last Posted Date: 2021-08-31

Lead Sponsor: IRIS Research and Development, LLC

Target Recruit Count: 10

Registration Number: NCT03419650

Locations: 🇺🇸
IRIS Research and Development, Plantation, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy